We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+17%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.33B
AUM Growth
+$1.78B
Cap. Flow
+$552M
Cap. Flow %
5.91%
Top 10 Hldgs %
20.52%
Holding
814
New
78
Increased
378
Reduced
271
Closed
33

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$50.3M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$39.4M
3
INTC icon
Intel
INTC
+$29.2M
4
QCOM icon
Qualcomm
QCOM
+$27.6M
5
DHR icon
Danaher
DHR
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 30.73%
2 Technology 19.55%
3 Financials 10.18%
4 Consumer Discretionary 9.32%
5 Communication Services 8.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NVDA icon
51
NVIDIA
NVDA
$5.01T
$37.4M 0.4%
6,361,520
+1,916,840
+43% +$9.97M
TECH icon
52
Bio-Techne
TECH
$11.2B
$37.4M 0.4%
681,228
+161,800
+31% +$8.49M
KO icon
53
Coca-Cola
KO
$354B
$36.6M 0.39%
660,667
+12,953
+2% +$696K
ALL icon
54
Allstate
ALL
$66.9B
$36M 0.39%
320,511
+89,264
+39% +$9.74M
UNP icon
55
Union Pacific
UNP
$183B
$35M 0.37%
193,380
+30,192
+19% +$5.17M
XOM icon
56
ExxonMobil
XOM
$651B
$34.9M 0.37%
499,591
-3,475
-0.7% -$240K
ADI icon
57
Analog Devices
ADI
$181B
$34.3M 0.37%
288,628
+73,807
+34% +$8.32M
SBUX icon
58
Starbucks
SBUX
$118B
$33.7M 0.36%
383,061
+9,697
+3% +$827K
ANSS
59
DELISTED
Ansys
ANSS
$32M 0.34%
124,468
+20,911
+20% +$4.95M
ITCI
60
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$30.6M 0.33%
893,000
-25,000
-3% -$300K
XRAY icon
61
Dentsply Sirona
XRAY
$2.59B
$29.9M 0.32%
529,136
+189,063
+56% +$10.5M
BIO icon
62
Bio-Rad Laboratories Class A
BIO
$8.42B
$29.4M 0.32%
79,494
+11,044
+16% +$3.89M
EMR icon
63
Emerson Electric
EMR
$82.9B
$29.4M 0.31%
385,157
+3,129
+0.8% +$225K
ORCL icon
64
Oracle
ORCL
$331B
$29.2M 0.31%
550,919
-55,128
-9% -$3.03M
ATVI
65
DELISTED
Activision Blizzard
ATVI
$29.1M 0.31%
489,868
+164,842
+51% +$9.13M
PTCT icon
66
PTC Therapeutics
PTCT
$6.37B
$28.9M 0.31%
601,990
-88,533
-13% -$3.76M
TJX icon
67
TJX Companies
TJX
$170B
$28.7M 0.31%
469,479
-74,795
-14% -$4.42M
ON icon
68
ON Semiconductor
ON
$33.8B
$28.4M 0.3%
1,165,584
+512,265
+78% +$10.8M
VIPS icon
69
Vipshop
VIPS
$6.84B
$28.4M 0.3%
+2,005,000
New +$23.8M
SPGI icon
70
S&P Global
SPGI
$126B
$28.1M 0.3%
102,770
+33,251
+48% +$8.64M
TSLA icon
71
Tesla
TSLA
$1.24T
$27.8M 0.3%
995,940
+274,440
+38% +$5.95M
JD icon
72
JD.com
JD
$40.8B
-152,287
Closed -$4.91M
BMRN icon
73
BioMarin Pharmaceuticals
BMRN
$11.5B
$27.3M 0.29%
322,415
-37,105
-10% -$2.8M
SHW icon
74
Sherwin-Williams
SHW
$78.3B
$27M 0.29%
139,023
+21,885
+19% +$4.17M
EA icon
75
Electronic Arts
EA
$52.4B
$26.6M 0.29%
247,399
+102,525
+71% +$10.2M

Similar funds

Candriam SCA's Q4 2019 Portfolio in Review

As of Q4 2019, Candriam SCA held 814 positions worth $9.33B, up 24% from $7.55B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Candriam SCA deployed $552M of net new capital in Q4 2019, opening 78 new positions and adding to 378 existing holdings. Its largest new stake was Vipshop: 2,005,000 shares worth $28.4M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Ra Pharmaceuticals, Inc. Common Stock, an estimated $49.9M trimmed.

  • Candriam SCA's largest Q4 2019 buy was Vipshop: 2,005,000 shares worth $28.4M.
  • Candriam SCA added most to Microsoft in Q4 2019, an estimated $50.3M increase.
  • Candriam SCA's biggest Q4 2019 reduction was Ra Pharmaceuticals, Inc. Common Stock, cutting an estimated $49.9M.
  • Candriam SCA fully exited Hilton Worldwide in Q4 2019, selling an estimated $11.8M.
  • Candriam SCA's ten largest holdings make up 21% of its $9.33B portfolio in Q4 2019.
  • Candriam SCA opened 78 new positions and closed 33 in Q4 2019.
  • Candriam SCA's portfolio value rose 24% quarter-over-quarter to $9.33B.

Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.